Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, Envoy Medical Inc’s stock clocked out at $0.8, down -0.03% from its previous closing price of $0.8. In other words, the price has decreased by -$0.03 from its previous closing price. On the day, 1.41 million shares were traded. COCH stock price reached its highest trading level at $0.865 during the session, while it also had its lowest trading level at $0.7842.
Ratios:
To gain a deeper understanding of COCH’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.46 and its Current Ratio is at 0.64.
Upgrades & Downgrades
In the most recent recommendation for this company, Ascendiant Capital Markets on June 24, 2024, initiated with a Buy rating and assigned the stock a target price of $8.50.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 11 ’25 when Patel Mona Chetan bought 2,500 shares for $1.47 per share. The transaction valued at 3,675 led to the insider holds 20,000 shares of the business.
Patel Mona Chetan bought 10,000 shares of COCH for $14,600 on Jun 06 ’25. The Director now owns 17,500 shares after completing the transaction at $1.46 per share. On May 27 ’25, another insider, BRYNELSEN CHARLES, who serves as the Director of the company, bought 35,000 shares for $1.65 each. As a result, the insider paid 57,673 and bolstered with 50,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, COCH now has a Market Capitalization of 22991786 and an Enterprise Value of 20381786. For the stock, the TTM Price-to-Sale (P/S) ratio is 109.48. Its current Enterprise Value per Revenue stands at 97.989 whereas that against EBITDA is -1.011.
Stock Price History:
The Beta on a monthly basis for COCH is 2.07, which has changed by -0.6495614 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, COCH has reached a high of $2.32, while it has fallen to a 52-week low of $0.64. The 50-Day Moving Average of the stock is -3.96%, while the 200-Day Moving Average is calculated to be -37.84%.
Shares Statistics:
It appears that COCH traded 2.90M shares on average per day over the past three months and 740650 shares per day over the past ten days. A total of 23.81M shares are outstanding, with a floating share count of 16.83M. Insiders hold about 41.55% of the company’s shares, while institutions hold 5.74% stake in the company. Shares short for COCH as of 1763078400 were 629475 with a Short Ratio of 0.22, compared to 1760486400 on 915182. Therefore, it implies a Short% of Shares Outstanding of 629475 and a Short% of Float of 3.6199997999999995.
Earnings Estimates
A comprehensive evaluation of Envoy Medical Inc (COCH) is underway, with the input of 1.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.28, with high estimates of -$0.25 and low estimates of -$0.3.
Analysts are recommending an EPS of between -$1.19 and -$1.19 for the fiscal current year, implying an average EPS of -$1.19. EPS for the following year is -$1.07, with 2.0 analysts recommending between -$0.95 and -$1.18.
Revenue Estimates
In. The current quarter, 1 analysts expect revenue to total $30k. It ranges from a high estimate of $30k to a low estimate of $30k. As of. The current estimate, Envoy Medical Inc’s year-ago sales were $42kFor the next quarter, 1 analysts are estimating revenue of $45k. There is a high estimate of $50k for the next quarter, whereas the lowest estimate is $40k.
A total of 1 analysts have provided revenue estimates for COCH’s current fiscal year. The highest revenue estimate was $200k, while the lowest revenue estimate was $200k, resulting in an average revenue estimate of $200k. In the same quarter a year ago, actual revenue was $225kBased on 2 analysts’ estimates, the company’s revenue will be $200k in the next fiscal year. The high estimate is $200k and the low estimate is $200k.
